Jesus Abraham Simón Campos

Author

Also Known As

Abraham Simon-Campos, Abraham Simón-Campos, Campos, J. Abraham Simon, J Abraham Simón-Campos, J Abraham-Simón, J. A. Simon‐Campos, J. Abraham Simon-Campos, J. Abraham Simón Campos, J. Abraham Simón-Campos, J. Campos

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Stanford University Pfizer (United States)Altoona Center for Clinical Research Center for Rheumatology Charité - Universitätsmedizin Berlin

About

Jesus Abraham Simón Campos is an author at Stanford University specializing in medicine, covid-19, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	665
2	Public Health	1	1	40
3	Critical Care Medicine	1	1	131
4	Epidemiology	1	1	40
5	Immunology	1	1	41

Jesus Abraham Simón Campos

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial Scott A. Halperin, Lingyun Ye, Donna MacKinnon‐Cameron, The Lancet VaccinationVaccine SafetyVaccine DevelopmentVaccine TrialVirology	2021	230
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial Hugh Montgomery, Richard Hobbs, Francisco Padilla, The Lancet Respiratory Medicine Covid-19 PandemicAntiviral TherapyPlacebo-controlled TrialMedicineIntramuscular Administration	2022	223
Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate M. C. Genovese, A. Covarrubias, G. Léon, Arthritis & Rheumatism	2011	194
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial Alexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen, The Lancet Respiratory Medicine Critical Care MedicineClinical Infectious DiseaseAnti-c5a AntibodyCovid-19 PandemicAntiviral Therapy	2022	131
Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19 Jennifer Hammond, Robert J. Fountaine, Carla Yunis, New England Journal of Medicine	2024	118
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis Jay Tuttle, Edit Drescher, Jesus Abraham Simón Campos, New England Journal of Medicine	2023	112
Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial Joel M. Kremer, Alan Kivitz, Jesus Abraham Simón Campos, Arthritis Research & Therapy	2015	54
Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study Christopher D. Buckley, Jesus Abraham Simón Campos, Brandon Becker, The Lancet Rheumatology InflammationRheumatologyRheumatoid DisorderAutoimmune DiseaseGranulocyte	2020	41
REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 Outpatients David M. Weinreich, Sumathi Sivapalasingam, Thomas Norton, Viral LoadCovid-19 PandemicClinical TrialsCovid-19 OutpatientsVaccine Trial	2021	40
Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial Yoav Golan, Jesus Abraham Simón Campos, Rob Woolson, Clinical Infectious Diseases	2022	40

Page 1